RxDoctor Payments Data

Matthew Braasch, MD

Urology · Edina, MNNPI 1578772554

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,174 of the $4,816 with a category attached, or 86.7%. It is spread thinly across 49 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations.

$4,816in general payments, 2019–2025

Across 153 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivators Inc.$500
  • Axonics, Inc.$444
  • Olympus America Inc.$435
  • Coloplast$399
  • 180 Medical, Inc.$319
  • Medtronic$274
  • plus $2K from 43 others

What the payments were for

  • Speaking & faculty fees$50010%
  • Food & beverage$4,17487%
  • Education$902%
  • Entertainment$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,816 in reported general payments places this provider in the 80th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$186,189
Medicare patients
454
Services billed
3,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide27$384,297
XtandiEnzalutamide17$231,869
MyrbetriqMirabegron112$99,796
GemtesaVibegron80$74,181
OrgovyxRelugolix24$62,625
Abiraterone Acetate45$61,248
Tamsulosin Hcl713$11,242
Finasteride498$7,135
Potassium Citrate ErPotassium Citrate29$2,742
Alfuzosin Hcl ErAlfuzosin Hcl94$2,645
Oxybutynin Chloride ErOxybutynin Chloride45$1,388
Trospium Chloride20$1,372
Silodosin26$1,363
Gentamicin Sulfate25$649
Dutasteride14$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$37$384,29727 claims
Astellas Pharma US IncXtandi, Myrbetriq$54$331,665129 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$13$136,806104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 urology providers in Minnesota.

Other urology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →